Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis

Medical Hypotheses

Volumn 63, Issue 6, 2004, Pages 1010-1013

  Altundag, Ozden ^a   Altundag, Kadri ^a,d   Selim Silay, Yavuz ^b   Gunduz, Mehmet ^c   Demircan, Kadir ^c   Gullu, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d USA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSPNEA; FEVER; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; METABOLIC BONE DISEASE; NAUSEA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 7044253113     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.04.022     Document Type: Article

References (20)

1. Coleman R.E., Rubens R.D. The clinical course of bone metastasis from breast cancer. Br. J. Cancer. 55:1987;61-66
2. Nielson O.S., Munro A.J., Tannock I.F. Bone metastasis: pathophysiology and management policy. J. Clin. Oncol. 9:1991;509-524
3. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27:2001;165-176
4. Hilner B.E., Ingle J.N., Chelbowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21:2003;4042-4057
5. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastasis in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21:2003;3150-3157
6. Roodman G.D. Mechanisms of bone metastasis. New Engl. J. Med. 350:2004;1655-1664
7. Kahn D., Weiner G.J., Ben-Haim S., Ponto L.L., Madsen M.T., Bushnell D.L., et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood. 83:1994;958-963. [Erratum, Blood 1994; 84: 3602]
8. Pfeilschifter J., Mundy G.R. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. P. Natl. Acad. Sci. USA. 84:1987;2024-2028
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1:1889;571-573
10. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. P. Natl. Acad. Sci. USA. 95:1998;3597-3602
11. Hofbauer L.C., Heufelder A.E. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur. J. Endocrinol. 139:1998;152-154
12. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319
13. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2:2002;584-593
14. Buchs N., Manen D., Bonjour J.P., Rizzoli R. Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cation-sensing mechanism. Eur. J. Endocrinol. 142:2000;500-505
15. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Wonderling D., Normand C., et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol. Assess. 8:2004;1-176
16. Berenson J.R., Rosen L.S., Howell A., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasis: A double-blind, randomized dose-response study. Cancer. 91:2001;1191-1200
17. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastasis in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 7:2001;377-387
18. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94:2002;1458-1468
19. Adami S., Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Safety. 14:1996;158-170
20. Aksoy S., Abali H., Dincer M., Kilickap S., Gullu I., Tekuzman G. Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties. Med. Hypoth. 62:2004;942-944